Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Capital Expenditures · Q4 FY2025 · quarter ended Dec 2025
Capital expenditures of -CN¥743.56K in Q4 FY2025
Q4 FY2025 capital expenditures was -CN¥743.56K. Over 3 fiscal years it compounded at -22.7% a year.
Context
- Capital expenditures amounted to 10.9% of revenue in FY2025, down 4.0 pp from a year earlier.
- Capital expenditures grew in size in 1 of the last 3 fiscal years.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
CNY · from the cash flow
- Latest · FY2025
- (12.63M) CNY
- Year-over-year change
- +54.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (12.63M) | +54.5% |
| FY2024 | 2024-12-31 | (27.77M) | -139.4% |
| FY2023 | 2023-12-31 | (11.6M) | +57.6% |
| FY2022 | 2022-12-31 | (27.33M) | -3.5% |
| FY2021 | 2021-12-31 | (26.4M) | — |
Capital Expenditures vs competitors
How ZYBT compares with its peers on the latest reported figures
- Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -54.5% is the 6th highest of 8, against a peer median of +50.8%.
- Capital expenditures amounts to 10.9% of revenue for ZYBT, versus a peer median of 2.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | CN¥12.63M CNY | -54.5% | -22.7% | 10.9% | |
| LTM Mar 2026 | $1.12M USD | +50.8% | +3.3% | 2.0% | |
| LTM Mar 2026 | $731K USD | +86.5% | -2.8% | 1282.5% | |
| LTM Mar 2026 | $373K USD | -70.4% | -9.3% | 0.5% | |
| LTM Mar 2026 | $221K USD | +380.4% | -44.0% | 2.9% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $196.47K USD | -29.5% | -3.0% | — |
| LTM Mar 2026 | CA$60.26K CAD | +102.4% | -31.1% | — | |
| LTM Mar 2026 | CA$15.65K CAD | -91.9% | -46.9% | — | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| Peer median (excluding ZYBT) | — | +50.8% | -9.3% | 2.5% | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 46.47M | 55.74M | 37.51M | 13.47M | (82.97M) |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| Deferred Income Tax | (358K) | (1.09M) | 758K | 924K | 11.1M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (33.71M) | (66.82M) | (20.49M) | (977K) | 44.83M |
| Accounts Receivables | (40.91M) | (47.38M) | 38.05M | 11.31M | 61.41M |
| Inventory | (12.34M) | (12.33M) | (12.9M) | (5.88M) | 6.25M |
| Accounts Payables | 17.63M | (9.67M) | (35.61M) | (404K) | (3.36M) |
| Other Working Capital | 1.91M | 2.56M | (10.03M) | (6M) | (19.47M) |
| Other Non-Cash Items | 3.4M | 10.7M | 6.5M | 3.47M | 14.42M |
| Operating Cash Flow | 31.81M | 17.34M | 48.18M | 41.05M | 13.33M |
| Capital Expenditures | (26.4M) | (27.33M) | (11.6M) | (27.77M) | (12.63M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.22M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.21M) | 0 | (3.15M) | (14.08M) | (11.62M) |
| Investing Cash Flow | (26.27M) | (27.33M) | (11.77M) | (27.67M) | (12.63M) |
| Debt Repayment | 8M | 34.88M | 24.97M | (2.74M) | (12.09M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 43.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.05M) | (21.43M) | (39.45M) | (16.02M) | 0 |
| Other Financing Activities | 0 | (1) | (4.5M) | (3.37M) | 1.32M |
| Financing Cash Flow | (3.05M) | 13.46M | (18.98M) | (22.13M) | 32.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 168K | (1.29M) |
| Net Change in Cash | 2.49M | 3.46M | 17.44M | (8.58M) | 31.73M |
| Free Cash Flow | 5.41M | (9.99M) | 36.58M | 13.27M | 703K |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.